地西他滨治疗骨髓增生异常综合征的疗效分析

冉俊丽; 韩伟

doi:10.7619/jcmp.202018027

地西他滨治疗骨髓增生异常综合征的疗效分析

冉俊丽¹,
韩伟²

1. 山东能源淄矿集团中心医院血液肿瘤科, 山东淄博, 255120;
2. 山东能源淄矿集团中心医院质管办, 山东淄博, 255120

详细信息

中图分类号: R733.3
计量
- 文章访问数: 266
- HTML全文浏览量: 16
- PDF下载量: 10
出版历程
- 收稿日期: 2020-07-12

Effects of decitabine in treatment of patients with myelodysplastic syndrome

RAN Junli¹,
HAN Wei²

1. Department of Hematology and Oncology, The Central Hospital of Shandong Energy Zibo Mining Group Co., Ltd, Zibo, Shandong, 255120;
2. Quality Management Office, The Central Hospital of Shandong Energy Zibo Mining Group Co., Ltd, Zibo, Shandong, 255120

摘要

摘要: 目的探讨地西他滨治疗骨髓增生异常综合征(MDS)的疗效及危险因素。方法收集65例MDS患者的临床资料,均接受地西他滨治疗,分析年龄、病程、国际预后积分系统(IPSS)分组、血小板计数等与疗效的关系,分析影响地西他滨治疗MDS效果的危险因素。结果所有患者治疗总有效率为78.46%。年龄、病程、IPSS分组、血小板计数与地西他滨治疗MDS的疗效有相关性,差异有统计学意义(P<0.05)。Logistic回归分析显示,年龄大、病程长、IPSS分组高、血小板计数低是影响地西他滨治疗MDS效果的危险因素(OR>1, P<0.05)。结论地西他滨治疗MDS效果显著,其效果与年龄、病程、IPSS分组、血小板计数有关。
- 骨髓增生异常综合征 /
- 地西他滨 /
- 国际预后积分系统 /
- 血小板计数 /
- 危险因素
Abstract: Objective To investigate the efficacy and risk factors of decitabine in the treatment of patients with myelodysplastic syndrome(MDS). Methods The clinical materials of 65 MDS patients with decitabine were collected. Relationships between efficacy and age, course of disease, grouping of International Prognostic Score System(IPSS), platelet count were analyzed. The risk factors affecting efficacy of decitabine in the treatment of MDS were analyzed. Results The total effective rate was 78.46% in all the patients. Age, course of disease, grouping of IPSS and platelet count were significantly correlated with the efficacy of decitabine in the treatment of MDS(P<0.05). Logistic regression analysis showed that older age, long course of disease, high grouping of IPSS and low platelet count were the risk factors affecting the efficacy of decitabine in the treatment of MDS(OR>1, P<0.05). Conclusion The decitabine is effective in the treatment of MDS, and its efficacy is related with age, course of disease, grouping of IPSS and platelet count.
- myelodysplastic syndrome /
- decitabine /
- International Prognostic Score System /
- platelet count /
- risk factors

HTML全文

参考文献(15)

张彦芳, 王育丽, 唐宇宏, 等. 低剂量地西他滨治疗骨髓增生异常综合征的临床观察[J]. 临床血液学杂志, 2018, 31(4): 546-548.

毛建平, 朱华渊, 沈文怡, 等. 超小剂量地西他滨治疗骨髓增生异常综合征37例疗效及安全性评价[J]. 中国实用内科杂志, 2017, 37(2): 141-144.

SOMMER S, CRUIJSEN M, CLAUS R, et al. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation[J]. Leuk Res, 2018, 72: 20-26.

JIAO A, MOERK CT, PENLAND N, et al. Regulation of skeletal myotube formation and alignment by nanotopographically controlled cellsecreted extracellular matrix[J]. J Biomed Mater Res A, 2018, 106(6): 1543-1551.

中华医学会血液学分会. 骨髓增生异常综合征诊断与治疗中国专家共识(2014年版)[J]. 中华血液学杂志, 2014, 35(11): 1042-1048.

CHESON B, GREENBERG P, BENNETT J, et al. Clinical application and proposal for modification of the International Working Group(IWG)response criteria in myelodysplasia[J]. Blood, 2006, 108(2): 419-425.

何国民, 陈婷, 徐娟, 等. 超小剂量地西他滨治疗骨髓增生异常综合征疗效分析[J]. 临床血液学杂志, 2017, 30(3): 55-57.

范枝俏, 樊文静, 吴涛, 等. 地西他滨治疗骨髓增生异常综合征研究进展[J]. 中国医师杂志, 2017, 19(8): 1272-1275.

秦剑, 黄姗, 聂波. 地西他滨治疗骨髓增生异常综合征37例临床疗效分析[J]. 昆明医科大学学报, 2017, 38(10): 112-116.

舒华娥, 方腾. 地西他滨治疗低中危骨髓增生异常综合征的疗效及患者生存预后因素分析[J]. 中国实验血液学杂志, 2020, 28(1): 214-217.

汪德珍, 朱轶男, 杨雪飞, 等. 地西他滨治疗骨髓增生异常综合征患者的临床疗效及其预后影响因素分析[J]. 医学临床研究, 2018, 35(7): 1431-1433.

冷青, 刘卓刚, 张晓东, 等. 超低剂量地西他滨治疗老年中、高危骨髓增生异常综合征的临床观察[J]. 实用药物与临床, 2017, 20(10): 1139-1143.

鲍振华, 赵洪国, 于虹娥. 地西他滨治疗骨髓增生异常综合征的临床观察及预后因素分析[J]. 中国实验血液学杂志, 2018, 26(6): 132-137.

常春康, 许峰. 骨髓增生异常综合征预后评分[J]. 天津医药, 2018, 46(8): 804-807.

马家乐, 李晓林, 张璞, 等. 地西他滨治疗骨髓增生异常综合征有效率的影响因素分析[J]. 中国医师杂志, 2018, 20(9): 1417-1420.